6533b852fe1ef96bd12ab696
RESEARCH PRODUCT
Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis
Joanna WegnerMohamad GoldustSebastian ZimmerShashank BhargavaStephan GrabbePetra Staubach-renzsubject
Liver CirrhosisMalemedicine.medical_specialtyCombination therapy610 MedizinDermatologyEtanerceptEtanerceptNephropathyDiabetic nephropathyPsoriatic arthritis610 Medical sciencesPsoriasisDiabetes MellitusmedicineHumansPsoriasisDiabetic Nephropathiesbusiness.industryArthritis PsoriaticMiddle Agedmedicine.diseaseDermatologyGuselkumabApremilastbusinessmedicine.drugdescription
Objective Treatment of recalcitrant moderate-to-severe psoriasis can be challenging. Combination therapy of biologics and immunosuppressive agents can be a new strategy for treating therapy-resistant cases with comorbidities, where many systemic medications are contraindicated. Case presentation We report a case of a 62-year-old diabetic man with a 30-year history of severe plaque psoriasis and psoriatic arthritis with cirrhosis and diabetic nephropathy that was treated successfully in combination with apremilast and etanercept after multiple previous unsuccessful treatment attempts. Conclusion There are no data supporting the combination of apremilast and etanercept in the management of recalcitrant cases of moderate-to-severe psoriasis and multiple comorbidities including psoriatic arthritis, diabetic nephropathy, and cirrhosis. In patients who do not respond to multiple approaches for the treatment of psoriasis, combination therapy with biologic agents and new systemic medications may lead to dramatic disease control.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-08-20 | Journal of Cosmetic Dermatology |